The state of Utah has terminated its engagement with the law firm Motley Rice LLC in its ongoing litigation against opioid manufacturers and distributors. This decision follows a motion filed by OptumRx, a pharmacy benefit manager, seeking to disqualify Motley Rice from representing Utah. OptumRx alleged that the firm had previously investigated the company on behalf of government entities and was now suing it in a private capacity, potentially violating ethical standards. ([law360.com](https://www.law360.com/articles/2372278/optumrx-moves-to-dq-motley-rice-in-utah-opioid-case?utm_source=openai))
In response, Motley Rice contended that any information obtained during its earlier involvement in government investigations was publicly available and not confidential, arguing against the disqualification. ([law360.com](https://www.law360.com/nativeamerican/articles/2384881/motley-rice-fights-optumrx-dq-bid-in-utah-opioid-suit?utm_source=openai))
Utah’s decision to sever ties with Motley Rice underscores the complexities and ethical considerations inherent in large-scale litigation involving multiple stakeholders. The state continues to pursue legal action against various entities implicated in the opioid crisis, aiming to secure resources for prevention and treatment initiatives.
In related developments, Utah has been actively involved in nationwide settlements with opioid manufacturers and distributors. In July 2025, the state announced its participation in a $720 million settlement with eight drug makers, potentially bringing up to $8.8 million to Utah. ([dcp.utah.gov](https://dcp.utah.gov/2025/07/10/utah-secures-720-million-nationwide-settlement-from-eight-opioid-drug-makers/?utm_source=openai))
These settlements are part of broader efforts to address the opioid epidemic, which has had a significant impact on communities across the state. Utah’s commitment to holding companies accountable reflects a concerted effort to mitigate the crisis and support affected individuals and families.